Abstracts tagged "Inflammation"

Abstract Number: 2211 • 2018 ACR/ARHP Annual Meeting
Technetium Tc 99m Tilmanocept: A Targeted Immunodiagnostic Radiopharmaceutical for the Assessment of Synovial Macrophage Activity in Rheumatoid Arthritis
Arash Kardan¹, Allison Kissling², Bonnie Abbruzzese², Ahmad Ismail², Rachael Hershey², Carley Hartings², David Ralph², Izabela Gierach², Michael Blue², Hannah Bailey², Christopher Gablemann², Katherine Repp² and Frederick Cope², ¹Charles F. Kettering Memorial Hospital and Wright State University Boonshoft School of Medicine, Dayton, OH, ²Navidea Biopharmaceuticals, Inc., Dublin, OH
Background/Purpose: Activated macrophages are a critical component of the inflammatory etiology of RA. It is well established that these macrophages perpetuate joint inflammation and destruction…
Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner¹, Anil K. Singh¹ and Salahuddin Ahmed^1,2, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…
Abstract Number: 2245 • 2018 ACR/ARHP Annual Meeting
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Anthony M. Reginato¹, Changqi Sun², Elsaid A. Khaled³, Tannin A. Schmidt⁴, Olin D. Liang⁵ and Gregory D Jay⁶, ¹Division of Rheumatology, Rhode Island Hospital, Providence, RI, ²Division of Rheumatology, Rhode Island Hospital, Providence, MA, ³Department of Biomedical and Phramaceutical Science, Chapman University School of Pharmacy, Irvine, CA, ⁴Biomedical Engineering, University of Connecticut Health Center, Framington, CT, ⁵Division of Hematology/Oncology, Rhode Island Hospital, Providence, RI, ⁶Department of Emergency Medicine, Rhode Island Hospital, Providence, RI
Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including…
Abstract Number: 1077 • 2018 ACR/ARHP Annual Meeting
Identification of Biomarkers Involved in the Resolution Phase of Inflammation: Specialized Pro-Resolving Mediator Receptors Expression in Rheumatoid Arthritis
Simone Perniola¹, Liliana Dinoia¹, Nunzia Lacarpia¹, Dorotea Natuzzi¹, Rita Bizzoca¹ and Florenzo Iannone², ¹Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ²D.E.T.O., Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy
Background/Purpose: Inflammation is part of the complex biological response of body tissues to harmful stimuli, involving immune cells, blood vessels, and molecular mediators. At the…
Abstract Number: 2264 • 2018 ACR/ARHP Annual Meeting
Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases
Anna Postolova¹ and Mark C. Genovese², ¹Department of Medicine, Stanford University Medical Center, Palo Alto, CA, ²Department of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Granulomatous Mastitis is a rare, inflammatory disease of the breast. Presenting symptoms in the breast can be unilateral or bilateral pain, masses, skin induration,…
Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Bidisha Dasgupta¹, Matthew Loza¹, Androniki Bili¹, Shruti Daga², Kurt Brown³, Jennifer Gilbride⁴, Benjamin Hsu¹ and Iain B. McInnes⁵, ¹Janssen Research & Development, LLC, Spring House, PA, ²GlaxoSmithKline, Uxbridge, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴Sum of Squares Ltd, Hertfordshire, United Kingdom, ⁵University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…
Abstract Number: 1568 • 2017 ACR/ARHP Annual Meeting
Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis
Ramnath Misra¹, Sandeep Kumar², Rajeev Singh³, Abhisek Singh⁴, Daisuke Kamimura⁵, Smriti Chaurasia², Yasunobu Aria⁶, Tori Austria⁷, Ratnadeep Mukherjee⁸, Balachandran Ravindran⁹, Vikas Agarwal² and Masaaki Murakami¹⁰, ¹Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Biochemistry, King George Medical University, Lucknow, India, ⁴Division of Molecular Neroimmunology, Post Doctoral Fellow, Sapporo, Japan, ⁵Molecular Neuroimmunology, Lecturer, Sapporo 060-0815,, Japan, ⁶Division of Molecular Neuroimmunology, Assistant Professor, Sapporo 060-0815, Japan, ⁷Division of Molecular Neuroimmunology, Special appointed - Assistant Professor, Sapporo 060-0815, Japan, ⁸Institute of Life Sciences, Ph D student, Bhubaneswar, India, ⁹Institute of Life Sciences, Distinguished Scientist, Bhubaneswar, India, ¹⁰Institute of Genetic Medicine, Director, Sapporo 060-0815, Japan
Background/Purpose: F759 mice with a single amino-acid substitution in signal transducer subunit of IL-6 receptor gp130 (Y759F) develops arthritisspontaneously due to IL-17A and IL-6 mediated…
Abstract Number: 2942 • 2017 ACR/ARHP Annual Meeting
One Year Changes in Ultrasound Findings in the Feet Are Associated with Patient Reported Outcomes but Not Clinical Examination: a Prospective Observational Study of Patients with Early Rheumatoid Arthritis
Hanyan Zou¹, Karen A. Beattie², George Ioannidis³ and Maggie Larche², ¹McMaster University, Hamilton, ON, Canada, ²Medicine, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Despite extensive involvement of the feet in early RA, few studies report clinical and imaging changes in the feet over time. In this observational…
Abstract Number: 642 • 2017 ACR/ARHP Annual Meeting
Downstream Effects of Apremilast in Human Arthritic Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Søren Lomholt², Morten Aagaard Nielsen², Line Dam Heftdal², Peter H. Schafer³ and Bent Deleuran^2,4, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Apremilast (Otezla) is a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, but the mechanisms of action of apremilast are not…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 697 • 2017 ACR/ARHP Annual Meeting
Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Valentin S. Schäfer¹, Katharina Weiss², Andreas Krause² and Wolfgang A. Schmidt³, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: ESR is applied for monitoring disease activity in SLE. It is known to be influenced by age and infections. We aimed at evaluating how…
Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
M. Elaine Husni¹, Vandana Rai², Marcia Leon Rabanal³ and Unnikrishnan Chandrasekharan⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…
Abstract Number: 864 • 2017 ACR/ARHP Annual Meeting
IL-9-Producing Innate Lymphoid Cells – Keyplayers That Orchestrate Resolution of Chronic Inflammation in Arthritis
Simon Rauber¹, Markus Luber¹, Stefanie Weber¹, Lisa Maul², Alina Soare³, Thomas Wohlfahrt¹, Aline Bozec⁴, Martin Herrmann⁵, Mario Zaiss², Ursula Fearon⁶, Douglas J. Veale⁷, Juan Canete⁸, Oliver Distler⁹, Felice Rivellese¹⁰, Costantino Pitzalis¹⁰, Georg Schett¹¹, Jörg Distler³ and Andreas Ramming¹², ¹Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Department Clinic of Medicine 3 - Immunology und Rheumatology, University of Erlangen-Nürnberg, Department Clinic of Medicine 3 - Immunology and Rheumatology, Erlangen, Germany, Erlangen, Germany, ⁵Medicine III, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Osterreich, Germany, ⁶Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁷Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁸Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain, ⁹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹⁰Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹¹Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ¹²Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Transition from acute to chronic inflammation is a key step in the pathogenesis of inflammatory disease but incompletely characterized to date. Similar to the…
Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting
Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations
Yann Becker¹, Renee Claude Loignon¹, Genevieve Marcoux¹, Anne-Sophie Julien², Imene Melki¹, Lihi Eder³, Eric Wagner¹, Martin Pelletier¹, Marie-Josee Hebert⁴, Clemence Belleannee¹, Joyce Rauch⁵, Melanie Dieude⁴, Paul R. Fortin⁶ and Eric Boilard¹, ¹CHU de Quebec and Universite Laval, Quebec City, QC, Canada, ²CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴CHUM and Universite de Montreal, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada
- Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…
Abstract Number: 967 • 2017 ACR/ARHP Annual Meeting
NF-κb-Inducing Kinase Regulates LTβR-Driven NF-κb Signaling and Inflammatory Activation of Endothelium
Paulina Kucharzewska¹, Chrissta Maracle², Jan Piet van Hamburg², Kim Jeucken², Henric Olsson¹ and Sander W. Tas³, ¹Bioscience, AstraZeneca, Göteborg, Sweden, ²2Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Sites of chronic inflammation, such as rheumatoid arthritis synovial tissue, are characterized by neovascularization and often contain tertiary lymphoid structures with characteristic features of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].